Before joining Schulman, Mr. Woods held several senior management positions in the medical device and biopharma services industry, including Aradigm Corporation where he led Business Development efforts to secure co-development and strategic partnering deals with pharmaceutical and biotech companies worldwide.
In nearly 30 years of work in the drug and medical device industries, Mr. Woods has had the opportunity to play a key role in the development of dozens of innovative products and services for a variety of organizations. His experience with both industry sponsors, research institutions and leading commercial research service providers forms the basis of a broad understanding of how to maximize the efficiency and effectiveness of development collaborations.
Mr. Woods has a MS in Molecular Biophysics and Biochemistry from Yale University, and a BS in Biology and Chemistry from Walla Walla University.
Dr. Henry brings more than 29 years of both hands-on and senior level clinical research experience in large pharmaceutical, biotechnology and contract research organizations. Eugenia has served as a statistical consultant and DMC member for many clients and has vast experience in communicating with the FDA for design and statistical issues. To date, Dr. Henry has been actively involved in 56 NDA/sNDA/ANDA/PMA submissions with 52 approvals.
Dr. Henry has leveraged her extensive expertise to create successful data management and statistical services companies such as HHI Clinical Research and Statistical Services which was sold to InVentiv in 2004. Dr. Henry then co-founded H2O Clinical Research in 2011 which merged with Pharma Start in 2016 and was rebranded to Firma Clinical Research in 2017. She has also served in similar roles at Pfizer as the head of Biostatistics and Data Management for the Department of Clinical Pharmacology and Experimental Medicine and at Novartis as the head of Biostatistics and Data Management for Medical Affairs. Dr. Henry received her Ph.D. in Biostatistics from the University of Missouri, Columbia.
As the company’s Chief Medical Officer, Dr. Henry will provide leadership and direction for Firma’s clinical development programs.
In 2011, Dr. Henry co-founded H2O Clinical which was rebranded to Firma Clinical Research in 2017. Prior to H2O, Dr. Henry served as the co-Chief Medical Officer of InVentiv Health and Chief Medical Officer of InVentiv Clinical Solutions.
Before InVentiv, Dr. Henry was Head of Clinical Research and Regulatory Affairs at Cephalon, Inc., Head of Clinical Research at Guilford Pharmaceuticals, and Global Head of Central Nervous System Clinical Research at the Sandoz Research Institute. Dr. Henry started his pharmaceutical career at Pfizer Central Research.
Dr. Henry received his medical degree from the University of Chicago (Pritzker) School of Medicine and his bachelor’s degree in Chemistry from the University of Illinois. He was a medical intern at the University of Chicago Hospitals and Clinics and trained in neurology and neuropathology at the Longwood Neurology Program in Boston, which included the Peter Bent Brigham Hospital, Beth Israel Hospital, and Boston Children’s Hospital. Prior to joining Pfizer, Dr. Henry was on staff at Boston Children’s Hospital and Harvard Medical School.
